| scholarly article | Q13442814 |
| P2093 | author name string | Remco J Molenaar | |
| Alwine B Kruisselbrink | |||
| Anne-Marie Cleton-Jansen | |||
| Judith V M G Bovée | |||
| Elisabeth F P Peterse | |||
| Yvonne de Jong | |||
| Arjen H G Cleven | |||
| Brendy E W M van den Akker | |||
| Ruben D Addie | |||
| Bertine Niessen | |||
| P2860 | cites work | Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. | Q38884358 |
| Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. | Q38901610 | ||
| Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. | Q39146561 | ||
| Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. | Q39149779 | ||
| Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. | Q39340562 | ||
| Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production | Q39393325 | ||
| Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study | Q41662722 | ||
| Chloroquine is a potent inhibitor of glutamate dehydrogenase in liver and kidney-cortex of rabbit | Q41929463 | ||
| Inhibitory properties of nerve-specific human glutamate dehydrogenase isozyme by chloroquine | Q41941868 | ||
| Targeting survivin as a potential new treatment for chondrosarcoma of bone | Q42419178 | ||
| Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. | Q48373123 | ||
| Outcome of advanced, unresectable conventional central chondrosarcoma. | Q50660686 | ||
| Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. | Q52015949 | ||
| Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. | Q52828622 | ||
| Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. | Q53361172 | ||
| Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. | Q54506099 | ||
| Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours | Q59348505 | ||
| Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance | Q82659226 | ||
| Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 | ||
| HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia | Q28300406 | ||
| AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 | Q28506431 | ||
| c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism | Q29617213 | ||
| Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis | Q33597162 | ||
| Estimated cause-specific survival continues to improve over time in patients with chondrosarcoma | Q33839039 | ||
| IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours | Q34186353 | ||
| Characterization of a newly derived human sarcoma cell line (HT-1080). | Q34202593 | ||
| Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. | Q34230316 | ||
| Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma | Q34314291 | ||
| Autophagy: assays and artifacts | Q34341096 | ||
| Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone | Q34396287 | ||
| Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. | Q34493791 | ||
| The clinical approach towards chondrosarcoma | Q34766148 | ||
| Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years | Q35302545 | ||
| Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability | Q35621293 | ||
| Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome | Q36190010 | ||
| Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation | Q36892224 | ||
| IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism | Q36948088 | ||
| Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells | Q37185828 | ||
| Metformin: taking away the candy for cancer? | Q37775372 | ||
| Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies | Q38165840 | ||
| Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours | Q38375735 | ||
| Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies | Q38674653 | ||
| Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line | Q38746885 | ||
| Prediction and validation of enzyme and transporter off-targets for metformin. | Q38838317 | ||
| Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4. | Q38838570 | ||
| Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. | Q38874166 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1074-1083 | |
| P577 | publication date | 2018-03-26 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation | |
| P478 | volume | 118 |
| Q100443903 | A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer |
| Q61807296 | Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway |
| Q91761588 | Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status |
| Q98778655 | Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma |
| Q64972730 | Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. |
Search more.